巴克斯德罗斯塔特:新一代的阿尔多激素合成酶抑制剂,为抗性高血压提供新的希望
Ewelina Młynarska1, Witold Czarnik1, Natasza Dzieża1
1Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.
Biomolecules
|October 29, 2025
概括
巴克斯德罗斯坦是一种新型的阿尔多氨酸合成酶抑制剂,通过降低阿尔多氨酸水平,有效降低耐性高血压患者的血压. 这种药物显示出有前途的安全性概况,并正在研究在心血管疾病管理中的更广泛应用.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗性高血压 (RH) 在心血管疾病管理方面存在重大挑战.
- 阿尔多氨酸合成酶抑制剂 (ASIs) 通过向阿尔多氨酸合成提供了一种新的治疗方法.
- 巴克斯德罗斯塔特是一种选择性的ASI,向CYP11B2,最大限度地降低了目标外的荷尔蒙效应.
研究的目的:
- 评估巴克斯德罗斯塔特在耐高血压患者的疗效和安全性.
- 评估巴克斯德罗斯塔特对阿尔多和血压的剂量依赖性影响.
- 探索巴克斯德罗斯塔特在阿尔多驱动高血压中的治疗潜力.
主要方法:
- 进行了2期临床试验 (BrigHTN和HALO),以评估巴克斯德罗斯塔特的作用.
- 耐药高血压患者接受了不同剂量的巴克斯德罗斯塔特或安慰剂.
- 血中阿尔多斯特水平,血压和安全参数都被监测.
主要成果:
- 巴克斯德罗斯塔特在保持皮质醇的同时,证明了血阿尔多素水平的剂量依赖性降低.
- 在BrigHTN试验中,随着2毫克的剂量,观察到压缩和压缩血压的显著降低.
- 哈洛试验表明了潜在的混因素,如改善的粘附性影响结果.
- 巴克斯德罗斯塔特具有良好的安全性,具有轻微的不良反应,对功能没有显著影响.
结论:
- 巴克斯德罗斯塔特是阿尔多驱动高血压的有希望的治疗选择,特别是在治疗耐药的病例中.
- 它选择性抑制阿尔多激素合成提供了有利的风险-益处概况.
- 进一步的研究正在进行中,以评估在慢性脏病和原发性高阿尔多斯特症中使用巴克斯德罗斯塔特.
更多相关视频
10:09Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
3.6K
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
673
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.2K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.2K
01:22Heart Failure Drugs: Diuretics
789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789